What Is Losartan?
Losartan is an angiotensin II receptor blocker (ARB) widely prescribed for the management of hypertension (high blood pressure) and for slowing kidney disease progression in patients with type 2 diabetes. It works by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict, thereby promoting vasodilation and lowering blood pressure. Losartan is one of the most extensively studied ARBs, with a well-established safety profile and proven cardiovascular protective effects.
Mechanism of Action
Losartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding and exerting its vasoconstrictive effects. This leads to relaxation of vascular smooth muscle, reduced peripheral vascular resistance, and decreased blood pressure. Unlike ACE inhibitors, losartan does not inhibit bradykinin breakdown, resulting in a lower incidence of cough as a side effect. The drug also reduces aldosterone secretion, promoting sodium and water excretion, which further contributes to blood pressure reduction. Losartan’s antihypertensive effect is typically evident within one week and reaches maximum effect within 3–6 weeks of continuous therapy.
Approved Uses
- Hypertension: First-line treatment for essential hypertension, either as monotherapy or in combination with other antihypertensives such as thiazide diuretics or calcium channel blockers.
- Diabetic Nephropathy: Slows the progression of kidney disease in patients with type 2 diabetes, proteinuria, and hypertension.
- Stroke Prevention: Reduces the risk of stroke in hypertensive patients with left ventricular hypertrophy.
- Heart Failure: May be used as part of combination therapy in select patients with heart failure who cannot tolerate ACE inhibitors.
Dosage Forms and Strengths
| Form | Strength | Typical Starting Dose | Maximum Dose |
|---|---|---|---|
| Tablet | 25 mg | 25–50 mg once daily | 100 mg daily |
| Tablet | 50 mg | 25–50 mg once daily | 100 mg daily |
| Tablet | 100 mg | 25–50 mg once daily | 100 mg daily |
Dosage adjustments are recommended for patients with hepatic impairment or those at risk of volume depletion. Losartan can be taken with or without food, but consistency in timing is advised.
Side Effects and Safety Profile
Losartan is generally well tolerated. Common side effects include dizziness, fatigue, nasal congestion, back pain, and mild gastrointestinal disturbances. Serious adverse effects are rare but may include angioedema, hyperkalemia, hypotension, and acute renal impairment in susceptible individuals. Patients should be monitored for electrolyte imbalances, especially potassium levels, and renal function periodically. Losartan is contraindicated during pregnancy (FDA Pregnancy Category D) as it can cause fetal injury or death. It should also be avoided in patients with bilateral renal artery stenosis or hypersensitivity to ARBs.
Comparison: Losartan vs Other ARBs
| Drug | Half-Life (hours) | Dosing Frequency | Key Differences |
|---|---|---|---|
| Losartan | 6–9 | Once or twice daily | First ARB developed; uricosuric effect |
| Valsartan | 6 | Once or twice daily | Higher AT1 receptor affinity |
| Olmesartan | 13 | Once daily | Longer half-life; less drug interactions |
| Candesartan | 9 | Once daily | Dual mechanism (parent + active metabolite) |
| Telmisartan | 24 | Once daily | Longest half-life; PPAR-γ agonist activity |
Clinical Efficacy and Key Studies
The cardiovascular protective effects of losartan have been demonstrated in several landmark clinical trials. The LIFE study (Losartan Intervention For Endpoint Reduction in Hypertension), published in The Lancet in 2002, randomized over 9,000 hypertensive patients with left ventricular hypertrophy to losartan or atenolol-based therapy. Losartan reduced the primary composite endpoint of cardiovascular mortality, stroke, and myocardial infarction by 13% compared to atenolol, despite equivalent blood pressure reduction. Notably, the stroke risk reduction was 25% greater with losartan. The RENAAL study (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) demonstrated that losartan reduced the risk of end-stage renal disease by 28% in patients with type 2 diabetes and nephropathy. These findings established losartan not only as an effective antihypertensive but also as a renoprotective and cardioprotective agent with benefits beyond blood pressure reduction alone.
Drug Interactions
Several clinically significant drug interactions should be considered when prescribing losartan. Concurrent use with potassium supplements, potassium-sparing diuretics (spironolactone, eplerenone, triamterene), or ACE inhibitors increases the risk of hyperkalemia. NSAIDs, particularly in elderly or volume-depleted patients, may diminish the antihypertensive effect and increase renal impairment risk. Rifampin and fluconazole can alter losartan metabolism via CYP2C9 and CYP3A4 pathways. Lithium levels may increase when co-administered with losartan, requiring therapeutic monitoring. Dual blockade of the renin-angiotensin system with combination ACE inhibitor and ARB therapy is generally not recommended due to increased adverse event risk without additional mortality benefit, as demonstrated in the ONTARGET trial.
Clinical Pharmacology and Pharmacokinetics
Following oral administration, losartan is well absorbed with systemic bioavailability of approximately 33%. It undergoes extensive first-pass metabolism in the liver, primarily via CYP2C9 and CYP3A4 isoenzymes, to form an active carboxylic acid metabolite (E-3174) that is 10–40 times more potent than the parent compound. The half-life of losartan is approximately 2 hours, while the active metabolite has a longer half-life of 6–9 hours, allowing for once-daily dosing. Peak plasma concentrations are achieved within 1 hour for losartan and 3–4 hours for the active metabolite. Food delays absorption slightly but does not significantly affect overall bioavailability. Approximately 99% of losartan and its metabolite are bound to plasma proteins, primarily albumin. Excretion occurs via both renal (35%) and biliary (60%) routes.
Special Population Considerations
Pediatric patients: Losartan is approved for use in hypertensive children aged 6 years and older. The starting dose is 0.7 mg/kg once daily, with a maximum of 1.4 mg/kg or 100 mg daily. Geriatric patients: No initial dose adjustment is typically required, but elderly patients may be more sensitive to blood pressure reduction effects and should be monitored for hypotension and electrolyte disturbances. Hepatic impairment: Lower starting doses (25 mg once daily) are recommended for patients with hepatic impairment due to reduced drug metabolism and increased systemic exposure. Renal impairment: No dose adjustment is necessary for renal impairment alone, but careful monitoring is required in patients with significant renal artery stenosis or those undergoing hemodialysis.
Patient Counseling Information
Patients should be advised to take losartan exactly as prescribed, preferably at the same time each day. They should not stop taking the medication abruptly, as hypertension is often asymptomatic but uncontrolled blood pressure carries significant cardiovascular risk. Patients should be counseled to avoid salt substitutes containing potassium chloride unless approved by their healthcare provider. Symptoms of hyperkalemia, including muscle weakness, fatigue, and palpitations, should be reported promptly. Women of childbearing potential must use effective contraception and immediately inform their healthcare provider if pregnancy is suspected. Over-the-counter NSAID use should be avoided due to potential blood pressure elevation and renal interaction. Patients should also be informed that therapeutic response typically requires 2–4 weeks of consistent therapy, with maximum antihypertensive effect observed at 3–6 weeks.
Available Brands and Manufacturers
In addition to the original brand Cozaar (Merck), numerous generic losartan formulations are manufactured worldwide. In India, major pharmaceutical companies including Torrent Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Cipla, Zydus Cadila, Aurobindo Pharma, and Lupin Limited produce high-quality generic losartan tablets that meet stringent bioequivalence standards. These manufacturers export to over 100 countries worldwide, ensuring global access to affordable losartan therapy. Many WHO-prequalified suppliers also list losartan on their procurement catalogs for low- and middle-income countries.
Indian Generic Pricing
India is a leading manufacturer of affordable generic losartan. Generic losartan 50 mg tablets from reputable Indian manufacturers are available at significantly lower prices compared to brand-name equivalents in Western markets. Typical retail prices for a month’s supply (30 tablets of 50 mg) from Indian pharmacies range between $2.70–$4.50, whereas brand-name Cozaar in the United States may cost $18–$36 per month without insurance. Prices may vary depending on the pharmacy, manufacturer, and whether purchasing through bulk or individual prescription. Always verify current pricing with licensed Indian pharmacies. For a complete range of affordable antihypertensive medications, explore our Blood Pressure Medications collection.
Frequently Asked Questions
Can losartan cause a persistent cough?
Is losartan safe for long-term use?
Can I take losartan with other blood pressure medications?
Does losartan interact with ibuprofen or other NSAIDs?
Safety Precautions
- Not recommended during pregnancy — can cause fetal harm or loss. Effective contraception should be used in women of childbearing potential.
- Monitor serum potassium regularly, especially in patients on potassium supplements, potassium-sparing diuretics, or with renal impairment.
- Use with caution in patients with pre-existing hypotension, hypovolemia, or severe hepatic impairment.
- Routine renal function monitoring is advised for all patients on long-term therapy.
References
- FDA Prescribing Information: Cozaar (losartan potassium). U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/
- 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6).
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
- Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet. 2002;359(9311):995–1003.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline NG136. 2019 (updated 2023).
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any medication. Drug prices shown are approximate ranges and may vary by location, pharmacy, and insurance coverage. Generic medications are bioequivalent to brand-name counterparts but may differ in appearance and excipients.
